精神医学52巻12号

2010年12月発行

研究と報告

SSRIsにaripiprazoleの追加投与が奏効した強迫性障害の13例

著者： 日隈晴香¹ 兼久雅之¹ 田中悦弘¹ 津留壽船¹ 花田浩昭¹ 穐吉條太郎¹

所属機関： ¹大分大学医学部精神神経医学講座

ページ範囲：P.1173 - P.1179

抄録

　強迫性障害の治療法として，選択的セロトニン再取り込み阻害薬(SSRIs)を中心とした薬物療法と認知行動療法を中心とした精神療法が確立している。しかし，これらの治療法でも十分に改善しない治療抵抗性の強迫性障害の患者に対して，aripiprazoleの強迫性障害に対する効果が報告されている。そこで我々は，SSRIsおよび認知行動療法にて2か月間以上改善を認めない強迫性障害患者13例に対して，増強療法としてaripiprazoleの追加を7週間試みた。8例の患者は，aripiprazoleの追加療法にて効果を示した。今回の結果は，治療抵抗性の強迫性障害において，aripiprazoleの併用療法は1つの有望な治療の選択肢であることを示唆している。

参考文献

1) Assie MB, Ravailhe V, Faucillor V, et al：Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neuro-chemical profile of novel antipsychotics：Frontocortical dopamine and hippocampal serotoninrelease in rat brain. J Pharmacol Exp Ther 315：265-272, 2005

2) Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al：A systematic review：Antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11：622-632, 2006

3) Block MH, Landeros-Weisenberger A, Rasario MC, et al：Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry 165：1532-1542, 2008

4) Burstein ES, Ma J, Wong S, et al：Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors：Identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 315：1278-1287, 2005

5) Chappell PB, Leckman JF, Riddle MA, et al：Neuroendocrine and behavioral effects of naloxone in Tourette syndrome. Adv Neurol 58：253-262, 1992

6) Choi YJ：Efficacy of treatments for patients with obsessive-compulsive disorder：A systematic review. J Am Acad Nurse Pract 21：207-213, 2009

7) Cobo Gómez JV, Fuste G, Coronas R, et al：Combination of aripiprazole and other psychopharmacological treatments in resistant and multi-resistant patients. Curr Drug Saf 3：210-215, 2009

8) Connor KM, Payne VM, Gadde KM, Zhang W, et al：The use of aripiprazole in obsessive-compulsive disorder：Preliminary observations in 8 patients. J Clin Psychiatry 66：49-51, 2005

9) Endicott J, Spitzer RL, Fleiss JL, et al：The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33：766-771, 1976

10) Fineberg NA, Gale T：Adding quetiapone to SRI in treatment-resistant obsessive-compulsive disorder：A randomized controlled treatment study. Int Clin Psychopharmacol 17：223-226, 2005

11) Fornaro M, Gabrielli F, Mattei C, et al：Aripiprazole augmentation in poor insight obsessive-compulsive disorder：A case report. Ann Gen Psychiatry 7：26, 2008

12) Goodman W, Price L, Rasmussen SA, et al：The Yale-Brown Obsessive-Compulsive Scale, Ⅰ：Development, use, and reliability. Arch Gen Psychiatry 46：1006-1011, 1989

13) Goodman W, Price L, Rasmussen SA, et al：The Yale-Brown Obsessive-Compulsive Scale, Ⅱ：Varidity. Arch Gen Psychiatry 46：1012-1016, 1989

14) Insel TR, Mueller EA, Alterman I, et al：Obsessive-compulsive disorder and serotonin：Is there a connection?　Biol Psychiatry 20：1174-1188, 1985

15) Insel TR, Pickar D：Naloxone administration in obsessive-compulsive disorder：Report of two cases. Am J Psychiatry 140：1219-1220, 1983

16) Insel TR, Zohar J：Obsessive-compulsive disorder：Psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 22：667-687, 1987

17) Kim SH, Nikolics L, Abbasi F, et al：Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents. J Psychiatr Res 44：493-498, 2010

18) Koran LM, Hanna GL, Hollander E, et al：Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 164(7 Suppl)：5-53, 2007

19) Kordon A, Wahl K, Koch N, et al：Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder：A double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 28：550-554, 2008

20) Lawler CP, Prioleau C, Lewis MM, et al：Interactions of the novel antipsychotic aripiprazole(OPC-14597)with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20：612-627, 1999

21) Matsubara K, Shimizu K, Suno M, et al：Tandspirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminargic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res 1112：126-133, 2006

22) Matsunaga H, Nagata T, Hayashida K, et al：A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry 70：863-868, 2009

23) Moran-Gates T, Massari C, Graurich A, et al：Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes. J Neurosci Res 84：675-682, 2006

24) Pallanti S, Baldini Rossi N, Sood E, et al：Nefazodone treatment of pathological gambling：A prospective open-label controlled trial. J Clin Psychiatry 63：1034-1039, 2002

25) Potkin SG, Saha AR, Kujawa MJ, et al：Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60：681-690, 2003

26) Saltz BL, Woerner MG, Robinson DG, et al：Side effects of antipsychotic drugs. Avoiding and minimizing their impact in elderly patients. Postgrad Med 107：169-172, 2000

27) Sandyk R：Naloxone abolishes obsessive-compulsive behavior in Tourette's syndrome. Int J Neurosci 35：93-94, 1987

28) Sarkar R, Klein J, Kruger S：Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder. Psychopharmacology 197：687-688, 2008

29) Shapiro DA, Renock S, Arrington E, et al：Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28：1400-1411, 2008

30) Starcevic V, Brakoulias V：Symptom subtypes of obsessive-compulsive disorder：Are they relevant for treatment?　Aust N Z J Psychiatry 42：651-661, 2008

31) Stark AD, Jordan S, Allers KA, et al：Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors：Functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology 190：373-382, 2007

32) Storch EA, Lehmkuhl H, Geffken GR, et al：Aripiprazole augmentation of imcomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress Anxiety 25：172-174, 2008

33) 住谷さつき，上野修一，石元康仁，他：強迫性障害のSSRIと非定型抗精神病薬に対する応答性と臨床特徴について．OCD研究会 編，宮岡等，上島国利 編集代表，強迫性障害の研究(8)．星和書店，pp31-38，2007

34) Tarazi FI, Zhang K, Baldessarini RJ：Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology 161：263-270, 2002

35) Yoshino T, Nishijima K, Katoh S, et al：Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A)receptors in the rat medial frontal cortex. Neurochem Int 40：355-360, 2002